

WORLD BIOSIMILARS CONFERENCE

Annual Conference on NEPHROLOGY AND UROLOGY

August 20-21, 2018
Chicago, USA



Ronald P Dudek

Lentigen Technology Inc., USA

The Adapter CAR™ Platform: From antibody to CAR T cell therapeutic

Chimeric antigen receptor engineered T cells (CAR T cells) have emerged as a new biologic immuno-oncology therapeutic category. Two flagship products have recently received FDA approval in the USA, both targeting the same tumor associated antigen, CD19. These products have demonstrated remarkable efficacy in treating patients with relapsed and refractory B-cell leukemia and lymphoma.

This presentation will review CAR T cell technology, the two approved products, and will introduce a novel universal CAR, the Adapter CAR™, that can enable any antibody to be used as a CAR T cell therapy. Also discussed will be manufacturing solutions for CAR T cells, including a novel benchtop automated system for the manufacture of CAR T cells, the CliniMACS Prodigy®.

Biography

Ronald P. Dudek, is the Director of Technology Development and Marketing and Adapter CAR Program Manager at Lentigen Technology, Inc. (LTI). Past President of Living Pharma, Inc., a universal CAR T cell company acquired by LTI June 29, 2017. Former Vice President of Commercial Strategy at Juno Therapeutics, Inc., and one of the first members of the company. Founding President of Restoration Oncology, Inc. (ROI), (founded January 2011), a CAR T cell company that developed anti-CD19 CAR T cells for the treatment of acute lymphoblastic leukemia and diffuse large B-cell lymphoma. The products, clinical program and intellectual property of ROI are now resident in Juno Therapeutics. 2005: Founded ImmunoStem, an off-the-shelf CAR T company, which could not raise financing in the negative investment environment at the time. Executive roles at leading cell therapy companies including Xcyte Therapies, Inc., Aastrom Biosciences, Inc., and Miltenyi Biotec, Inc., 8 years of immunology research experience (Scripps Research Institute, Hybritech, Inc.), and 25 years of overall biotechnology business experience.

Ron.Dudek@lentigen.com

Notes: